Rhonda M. Chicko - 07 Aug 2025 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Role: Chief Financial Officer
Signature: /s/ Rhonda Chicko
Issuer symbol: CYCN
Transactions as of: 07 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 11 Aug 2025, 16:05:06 UTC
Previous filing: 11 Mar 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
CHICKO RHONDA M.	Chief Financial Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE	/s/ Rhonda Chicko	11 Aug 2025	0001740376

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYCN	Stock Option (Right to Buy)	Award	$0	+25,000		$0.000000	25,000	07 Aug 2025	Common Stock	25,000	$2.36	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted an option to purchase up to 25,000 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan. These 25,000 shares vest as follows: (i) 8,750 shares are immediately exercisable, and (ii) the remaining 16,250 shares vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remains as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

Content

The Reporting Person was granted an option to purchase up to 25,000 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan. These 25,000 shares vest as follows: (i) 8,750 shares are immediately exercisable, and (ii) the remaining 16,250 shares vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remains as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.